BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

PHASE3CompletedINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

September 1, 2023

Study Completion Date

November 18, 2024

Conditions
Pleural Mesothelioma Malignant Advanced
Interventions
DRUG

Carboplatin

Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.

DRUG

Pemetrexed

Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.

DRUG

Bevacizumab

Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.

DRUG

Atezolizumab

Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.

Trial Locations (42)

Unknown

University Hospital Leuven, Leuven

CHU Liege, Liège

Unicancer - Institut Bergonie, Bordeaux

Caen- CHU, Caen

Le Mans - CHG, Le Mans

Lyon - Centre Léon Bérard, Lyon

Hospital Nord, Marseille

Curie Cancer Center Paris, Paris

Toulouse - CHU, Toulouse

Tours - CHU, Tours

SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria

IRCCS Instituto Tumori Giovanni Paolo II, Bari

Fondazione IRCCS Istituto Nazionale die Tumori, Milan

Instituto Europeo di Oncologia (IEO), Milan

AULSS2 Marca Trevigiana Treviso, Treviso

University Hospital of Turin, Turin

Alicante University Hospital ISABIAL, Alicante

ICO Hospitalet, Barcelona

Vall Hebron University Hospital/Vall Hebron Institue Oncology, Barcelona

Puerta de Hierro Hospital, Majadahonda

Hospital Parc Tauli Sabadell, Sabadell

Virgen del Rocio, Seville

Complexo Hospitalario Universitario de Vigo, Vigo

Kantonsspital Aarau, Aarau

Istituto Oncologica della Svizzera Italiana, Bellinzona

Ferdinando Cerciello, Bern

Kantonsspital Graubünden, Chur

CHUV, Lausanne

Luzerner Kantonsspital, Lucerne

Kantonsspital St. Gallen, Sankt Gallen

Kantonsspital Winterthur, Winterthur

UniversitätSpital Zürich, Zurich

Addenbrooke's Hospital, Cambridge

Clatterbridge Cancer Centre, Liverpool

Guy's and St Thomas' Hospital, London

Royal Marsden Hospital (Fulham Road), London

Royal Marsden Hospital (Sutton), London

Kent Oncology Centre, Maidstone

Wythenshawe Hospital, Manchester

Plymouth Hospitals NHS Trust, Plymouth

Weston Park Hospital, Sheffield

Royal Cornwall Hospital, Truro

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

ETOP IBCSG Partners Foundation

NETWORK

NCT03762018 - BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter